Long dosing intervals in the treatment of postmenopausal osteoporosis

References

• Fast facts. National Osteoporosis Foundation. Washington, DC: National Osteoporosis Foundation. Available at: www.nof.org/osteoporosis/diseasefacts.htm [Last accessed 25 January 2007]
   Google Scholar
• Medications to prevent and treat osteoporosis. National Institutes of Health. Bethesda, Md: National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: www.niams. nih.gov/bone/hi/osteoporosis_medicine.htm [Last accessed 4 February 2007]
   Google Scholar
• Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194(Suppl):S3–11
   Google Scholar
• Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737–42
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005;16:155–62
   PubMed Web of Science ®Google Scholar
• LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39–51
   PubMedGoogle Scholar
• Crews JE, Campbell VA. Vision impairment and hearing loss among community-dwelling older Americans: implications for health and functioning. Am J Public Health 2004;94:823–9
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38–42
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3–7
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 2005;16:134–41
   Google Scholar
• Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334–8
   PubMed Web of Science ®Google Scholar
• Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 2004;15:767–78
   Google Scholar
• Recker R, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–61
   Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22
   PubMed Web of Science ®Google Scholar
• Reginster JY, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005;90:5018–24
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al., for the Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al., for the Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women‘s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   Google Scholar
• Cauley JA, Robbins J, Chen Z, et al., for the Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women‘s Health Initiative randomized trial. JAMA 2003;290:1729–38
   Google Scholar
• Compston JE, Watts NB. Combination therapy for post-menopausal osteoporosis. Clin Endocrinol (Oxf) 2002;56:565–9
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45
   Google Scholar
• Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and non vertebral fractures: results from the MORE trial. Bone 2003;33:522–32
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al., for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727–41
   Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al., for the Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxi fene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–37
   Google Scholar
• Miacalcin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2003
   Google Scholar
• Chesnut CH 3rd, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res 2005;20: 1548–61
   Google Scholar
• Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109: 267–76
   Google Scholar
• Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2004
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in post menopausal women with osteoporosis. N Engl J Med 2001;344:1434–41
   PubMed Web of Science ®Google Scholar
• Miller PD, Bilezikian JP, Diaz-Curiel M, et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007 Jul 3; [Epub ahead of print]
   Google Scholar
• Actonel [package insert]. Kansas City, MO: Aventis Pharmaceuticals, 2005
   Google Scholar
• Boniva [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2006
   Google Scholar
• Fosamax [package insert]. Whitehouse Station, NJ: Merck and Company, 2005
   Google Scholar
• Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services; 2004
   Google Scholar
• Rizzoli R. Long term outcome of weekly bisphosphonates. Clin Orthop Relat Res 2006;443:61–5
   PubMedGoogle Scholar
• Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423–33
   PubMed Web of Science ®Google Scholar
• Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 2005;37:433–40
   PubMed Web of Science ®Google Scholar
• Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36:315–28
   PubMed Web of Science ®Google Scholar
• Muhlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6: 1003–11
   Google Scholar
• Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Greenspan SL, Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treat ment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988–96
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
   Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433–9
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344: 333–40
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757–64
   PubMed Web of Science ®Google Scholar
• Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15: 792–8
   Google Scholar
• Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006;65:654–61
   PubMed Web of Science ®Google Scholar
• Recker RR, Weinstein RS, Chesnut CH 3rd, et al. Histomorpho-metric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004;15: 231–7
   Google Scholar
• Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every 3 months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003;62:969–75
   PubMed Web of Science ®Google Scholar
• Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2005
   Google Scholar
• Reclast [package insert] East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2007
   Google Scholar
• Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653–61
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Zoledronate once-yearly increases bone mineral density – implications for osteoporosis. Expert Opin Pharmacother 2002;3:1007–9
   PubMedGoogle Scholar
• McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–31
   PubMed Web of Science ®Google Scholar
• Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059–66
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165: 2414–19
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903
   PubMed Web of Science ®Google Scholar
• Ettinger MP, Felsenberg D, Harris ST, et al. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol 2005;32:1968–72
   PubMed Web of Science ®Google Scholar
• Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 2006;17: 1638–44
   Google Scholar
• Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89: 1117–23
   Google Scholar